Epizyme is a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $496M
Founded date: 2007
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Kleiner Pe... | kleinerper... |
| - | Foresite C... | foresiteca... |
| - | Ridgeback ... | ridgebackc... |
| - | Bay City C... | baycitycap... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 06.11.2020 | - | $150M | - |
| 05.11.2019 | - | $270M | - |
| 22.04.2014 | - | $4M | - |
| 08.12.2009 | Series B | $40M | New Enterp... |
| 07.10.2009 | Series B | $32M | - |
Mentions in press and media 16
| Date | Title | Description |
| 13.08.2024 | Myrobalan Therapeutics: Additional $9 Million Raised And Grant Bogle Joins Board | Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announced the appointment of Grant C. Bog... |
| 19.12.2019 | FDA panel recommends approval of Epizyme drug for rare cancer | Shares of Epizyme rose 35.6% on the Nasdaq Wednesday following the news, before leveling off and by Thursday afternoon trading at around 8% above their Wednesday closing price. “We are incredibly pleased by ODAC’s unanimous support for the ... |
| 05.11.2019 | Epizyme Raises Up to $270M in Funding | Epizyme, Inc. (Nasdaq: EPZM), a Cambridge, Mass.-based late-stage biopharmaceutical company developing novel epigenetic therapies, closed funding agreements that, in aggregate, could bring in up to $270m in capital. The backers were Royalty... |
| 25.07.2019 | FDA to make decision on Epizyme drug for rare cancer by January 2020 | Epizyme’s shares fell nearly 11 percent on the Nasdaq when markets opened Thursday, but quickly recovered their value and are currently up nearly 1 percent from their Wednesday closing price. Data from the 62 patients were shown in an oral ... |
| 12.03.2015 | Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438 | CAMBRIDGE, Mass., Mar 12, 2015 (BUSINESS WIRE) — Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that it has reacquired global rights to its EZH2 program,... |
| 22.04.2014 | Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments | Cambridge, MA — Epizyme, Inc. EPZM +9.15% , a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milest... |
| 30.10.2013 | Which venture capital firm’s healthcare investment picks secured the most IPOs? | I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals. Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The ... |
| 26.04.2012 | Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration | Celgene also has a phase 3 trial under way that is using the Abraxane in the treatment of metastatic pancreatic cancer with data expected in the second half of 2012 or the first half of 2013. It has at least six late-stage clinical trials u... |
| 08.12.2009 | Epizyme Closes $40M Series B Financing adding NEA to Investor Syndicate | Epizyme, Inc., a Cambridge, MA-based biopharmaceutical company that creates innovative drugs for major diseases based on discoveries emerging from the field of epigenetics, announced the participation of New Enterprise Associates (NEA) in i... |
| 07.10.2009 | USA, Epizyme Closes $32M Series B Financing | Cambridge, MA-based Epizyme, Inc., a biopharmaceutical company founded in 2007 to create innovative drugs for major diseases based on new discoveries emerging from the field of epigenetics, closed a $32m Series B financing led by new invest... |
Show more